NCT03920319 is a Phase 1 clinical trial of Bupropion in Smoking, sponsored by University of California, Los Angeles.

Who is sponsoring NCT03920319?

NCT03920319 is sponsored by University of California, Los Angeles.

What drugs are being tested in NCT03920319?

Interventions in NCT03920319: Bupropion, Placebo.

What condition does NCT03920319 study?

NCT03920319 studies Smoking, Smoking, Tobacco.

Is NCT03920319 still recruiting?

NCT03920319 is currently completed. Last updated 18 April 2019.

Last reviewed 2019-04-18 · How we verify

NCT03920319

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bupropion and Cigarette-Related Cues in Smokers

Completed Phase 1 Last updated 18 April 2019

What this trial tests

Phase 1 trial testing Bupropion in Smoking in 34 participants. Completed in 31 December 2005.

Timeline

1 January 2004

Primary endpoint
31 December 2005

31 December 2005

Quick facts

Lead sponsor	University of California, Los Angeles
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	basic science
Enrollment	34
Start date	1 January 2004
Primary completion	31 December 2005
Estimated completion	31 December 2005

Drugs / interventions tested

Bupropion (bupropion) — full drug profile →
Placebo

Conditions studied

Smoking — all drugs for Smoking →
Smoking, Tobacco — all drugs for Smoking, Tobacco →

Sponsor

University of California, Los Angeles

Who can join

Adults 18 to 65, any sex, with Smoking or Smoking, Tobacco. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Randomized, double-blind, before-after controlled trial to assess changes in regional brain activation in response to cigarette-related cues from before to after treatment with bupropion (vs placebo).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Antidepressants for smoking cessation.
Howes S, Hartmann-Boyce J, Livingstone-Banks J, Hong B, et al · · 2020 · cited 66× · PMID 32319681 · DOI 10.1002/14651858.cd000031.pub5
Antidepressants for smoking cessation.
Hajizadeh A, Howes S, Theodoulou A, Klemperer E, et al · · 2023 · cited 38× · PMID 37230961 · DOI 10.1002/14651858.cd000031.pub6

Verify or expand the search:

Other trials of Bupropion

Trials testing the same drug.

NCT07223671 — Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy · Phase 1 · completed
NCT07235748 — Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvas · Phase 1 · completed
NCT06973005 — A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Buprop · Phase 1 · completed
NCT05603104 — Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First- · Phase 3 · recruiting
NCT05973786 — The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in · Phase 3 · recruiting

Other recruiting trials for Smoking

Currently open trials in the same condition.

NCT07488741 — Comparison of the Effects of Different Chest Techniques on University Students With Smoking Addiction · NA · recruiting
NCT07443631 — Assessment of HPHC Exposure in Smokers Switching to THS/TP18 With Different Device Variants · NA · recruiting
NCT07132814 — Abuse Liability for Five Modern Oral Nicotine Products · NA · recruiting
NCT06966258 — Inspire HER: Inspiring the Heart and Emotions for Radical Health · NA · recruiting
NCT06713603 — Technology Assisted Motivational Interviewing · NA · recruiting

Other University of California, Los Angeles trials

Trials by the same sponsor.

NCT04846517 — rTMS for Aneroxia Nervosa in Youth · NA · not yet recruiting
NCT06701760 — Sodium Lactate in Severe TBI · Phase 2 · not yet recruiting
NCT04996667 — Effect of iNO in Patients With Submassive and Massive PE · Phase 2 · withdrawn
NCT05067387 — Evaluation of Oral THC and CBD in Men and Women · Phase 1 · not yet recruiting
NCT07534696 — Evaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03920319 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Los Angeles
Last refreshed: 18 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03920319.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing